Vir Biotechnology (NASDAQ:VIR) EVP Sells $15,216.19 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 1,343 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $11.33, for a total value of $15,216.19. Following the transaction, the executive vice president directly owned 112,600 shares in the company, valued at approximately $1,275,758. The trade was a 1.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 3rd, Vanina de Verneuil sold 2,407 shares of Vir Biotechnology stock. The shares were sold at an average price of $11.10, for a total value of $26,717.70.

Vir Biotechnology Price Performance

Shares of VIR stock opened at $12.21 on Friday. The stock’s 50-day moving average is $11.03 and its two-hundred day moving average is $9.61. The firm has a market cap of $2.07 billion, a P/E ratio of -9.69 and a beta of 1.70. Vir Biotechnology, Inc. has a fifty-two week low of $4.82 and a fifty-two week high of $12.45.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.18. The company had revenue of ($0.19) million during the quarter, compared to analyst estimates of $0.98 million. During the same period in the prior year, the firm posted ($1.17) EPS. Vir Biotechnology’s revenue was down 178.3% compared to the same quarter last year. As a group, research analysts expect that Vir Biotechnology, Inc. will post -1.84 EPS for the current year.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Analyst sentiment improved: Needham raised its price target to $20 from $18 and maintained a Buy rating. Zacks Research also upgraded VIR from Strong Sell to Hold, reducing a bearish signal. Needham rating Zacks rating
• Positive Sentiment: Key clinical catalyst ahead: Vir plans to present topline Phase 3 ECLIPSE 1 results for elebsiran and tobevibart in chronic hepatitis delta at AASLD’s 2026 liver meeting. Positive data could be a meaningful catalyst, though the outcome is uncertain. AASLD data presentation
• Positive Sentiment: Cash runway extends into the second half of 2028, giving the company additional time to advance its pipeline and reach development milestones. Cash runway update
• Neutral Sentiment: Q3 loss beat expectations: Vir reported a loss of $0.57 per share, narrower than analysts’ expected loss of about $0.75–$0.80 and the $1.17 loss a year earlier. Q3 results
• Neutral Sentiment: An executive sold a small number of shares under a pre-arranged plan to cover tax withholding on vested equity awards; the stated purpose makes this less indicative of a change in outlook. SEC filing
• Negative Sentiment: Revenue missed sharply: Q3 revenue was negative $0.19 million versus analysts’ estimate of $0.98 million, and was down 178.3% year over year, tempering the earnings beat. Revenue results

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VIR. BlackRock Inc. acquired a new position in shares of Vir Biotechnology during the second quarter valued at $210,712,000. ARCH Venture Management LLC acquired a new position in Vir Biotechnology in the 2nd quarter valued at approximately $129,353,521. ADAR1 Capital Management LLC bought a new stake in shares of Vir Biotechnology in the 1st quarter worth $24,593,000. Dimensional Fund Advisors LP boosted its position in shares of Vir Biotechnology by 1.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,579,678 shares of the company’s stock valued at $23,107,000 after acquiring an additional 43,401 shares during the last quarter. Finally, Bank of America Corp DE purchased a new stake in Vir Biotechnology in the second quarter worth about $11,642,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on VIR shares. Needham & Company LLC upped their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday. Morgan Stanley set a $25.00 price target on shares of Vir Biotechnology in a research report on Thursday, August 6th. Zacks Research upgraded Vir Biotechnology from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Wall Street Zen upgraded shares of Vir Biotechnology from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average price target of $22.14.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.